PDCD1 and non-small cell lung carcinoma: Five of these studies focused on statins, and the researchers found that patients on statins with NSCLC and malignant pleural mesothelioma (MPM) treated with PD-1 blockade showed improvement in progression free survival and overall survival, compared to non-statin users [OS: HR 0.76, 95% CI (0.63–0.92), P = .005; PFS: HR 0.86, 95% CI (0.75–0.99), P = .036)] (44).